Cargando…

Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype

BACKGROUND: Trained immunity – or innate immune memory – can be described as the long-term reprogramming of innate immune cells towards a hyperresponsive state which involves intracellular metabolic changes. Trained immunity has been linked to atherosclerosis. A subgroup of patients with primary Sjö...

Descripción completa

Detalles Bibliográficos
Autores principales: Huijser, Erika, van Helden-Meeuwsen, Cornelia G., Grashof, Dwin G. B., Tarn, Jessica R., Brkic, Zana, Huisman, Josje M. A., Wahadat, M. Javad, van de Werken, Harmen J. G., Lopes, Ana P., van Roon, Joel A. G., van Daele, Paul L. A., Kamphuis, Sylvia, Ng, Wan-Fai, Bekkering, Siroon, Joosten, Leo A. B., Dik, Willem A., Versnel, Marjan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289449/
https://www.ncbi.nlm.nih.gov/pubmed/35860283
http://dx.doi.org/10.3389/fimmu.2022.840751
_version_ 1784748668258091008
author Huijser, Erika
van Helden-Meeuwsen, Cornelia G.
Grashof, Dwin G. B.
Tarn, Jessica R.
Brkic, Zana
Huisman, Josje M. A.
Wahadat, M. Javad
van de Werken, Harmen J. G.
Lopes, Ana P.
van Roon, Joel A. G.
van Daele, Paul L. A.
Kamphuis, Sylvia
Ng, Wan-Fai
Bekkering, Siroon
Joosten, Leo A. B.
Dik, Willem A.
Versnel, Marjan A.
author_facet Huijser, Erika
van Helden-Meeuwsen, Cornelia G.
Grashof, Dwin G. B.
Tarn, Jessica R.
Brkic, Zana
Huisman, Josje M. A.
Wahadat, M. Javad
van de Werken, Harmen J. G.
Lopes, Ana P.
van Roon, Joel A. G.
van Daele, Paul L. A.
Kamphuis, Sylvia
Ng, Wan-Fai
Bekkering, Siroon
Joosten, Leo A. B.
Dik, Willem A.
Versnel, Marjan A.
author_sort Huijser, Erika
collection PubMed
description BACKGROUND: Trained immunity – or innate immune memory – can be described as the long-term reprogramming of innate immune cells towards a hyperresponsive state which involves intracellular metabolic changes. Trained immunity has been linked to atherosclerosis. A subgroup of patients with primary Sjögren’s syndrome (pSS) exhibits systemic type I interferon (IFN) pathway activation, indicating innate immune hyperactivation. Here, we studied the link between type I IFNs and trained immunity in an in vitro monocytic cell model and peripheral blood mononuclear cells (PBMCs) from pSS patients. METHODS: The training stimuli heat killed Candida albicans, muramyl dipeptide, IFNβ, and patient serum were added to THP-1 cells for 24 hours, after which the cells were washed, rested for 48 hours and subsequently re-stimulated with LPS, Pam3Cys, poly I:C, IFNβ or oxLDL for 4-24 hours. PBMCs from pSS patients and healthy controls were stimulated with LPS, Pam3Cys, poly I:C or IFNβ for 0.5-24 hours. RESULTS: Training with IFNβ induced elevated production of pro-atherogenic cytokines IL-6, TNFα and CCL2, differential cholesterol- and glycolysis-related gene expression, and increased glucose consumption and oxLDL uptake upon re-stimulation. Type I IFN production was increased in Candida albicans- and IFNβ-trained cells after LPS re-stimulation, but was reduced after poly I:C re-stimulation. Training with muramyl dipeptide and IFNβ, but not Candida albicans, affected the IFN-stimulated gene expression response to IFNβ re-stimulation. PBMCs from pSS patients consumed more glucose compared with healthy control PBMCs and tended to produce more TNFα and type I IFNs upon LPS stimulation, but less type I IFNs upon poly I:C stimulation. CONCLUSIONS: Type I IFN is a trainer inducing a trained immunity phenotype with pro-atherogenic properties in monocytes. Conversely, trained immunity also affects the production of type I IFNs and transcriptional response to type I IFN receptor re-stimulation. The phenotype of pSS PBMCs is consistent with trained immunity. This connection between type I IFN, trained immunity and cholesterol metabolism may have important implications for pSS and the pathogenesis of (subclinical) atherosclerosis in these patients.
format Online
Article
Text
id pubmed-9289449
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92894492022-07-19 Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype Huijser, Erika van Helden-Meeuwsen, Cornelia G. Grashof, Dwin G. B. Tarn, Jessica R. Brkic, Zana Huisman, Josje M. A. Wahadat, M. Javad van de Werken, Harmen J. G. Lopes, Ana P. van Roon, Joel A. G. van Daele, Paul L. A. Kamphuis, Sylvia Ng, Wan-Fai Bekkering, Siroon Joosten, Leo A. B. Dik, Willem A. Versnel, Marjan A. Front Immunol Immunology BACKGROUND: Trained immunity – or innate immune memory – can be described as the long-term reprogramming of innate immune cells towards a hyperresponsive state which involves intracellular metabolic changes. Trained immunity has been linked to atherosclerosis. A subgroup of patients with primary Sjögren’s syndrome (pSS) exhibits systemic type I interferon (IFN) pathway activation, indicating innate immune hyperactivation. Here, we studied the link between type I IFNs and trained immunity in an in vitro monocytic cell model and peripheral blood mononuclear cells (PBMCs) from pSS patients. METHODS: The training stimuli heat killed Candida albicans, muramyl dipeptide, IFNβ, and patient serum were added to THP-1 cells for 24 hours, after which the cells were washed, rested for 48 hours and subsequently re-stimulated with LPS, Pam3Cys, poly I:C, IFNβ or oxLDL for 4-24 hours. PBMCs from pSS patients and healthy controls were stimulated with LPS, Pam3Cys, poly I:C or IFNβ for 0.5-24 hours. RESULTS: Training with IFNβ induced elevated production of pro-atherogenic cytokines IL-6, TNFα and CCL2, differential cholesterol- and glycolysis-related gene expression, and increased glucose consumption and oxLDL uptake upon re-stimulation. Type I IFN production was increased in Candida albicans- and IFNβ-trained cells after LPS re-stimulation, but was reduced after poly I:C re-stimulation. Training with muramyl dipeptide and IFNβ, but not Candida albicans, affected the IFN-stimulated gene expression response to IFNβ re-stimulation. PBMCs from pSS patients consumed more glucose compared with healthy control PBMCs and tended to produce more TNFα and type I IFNs upon LPS stimulation, but less type I IFNs upon poly I:C stimulation. CONCLUSIONS: Type I IFN is a trainer inducing a trained immunity phenotype with pro-atherogenic properties in monocytes. Conversely, trained immunity also affects the production of type I IFNs and transcriptional response to type I IFN receptor re-stimulation. The phenotype of pSS PBMCs is consistent with trained immunity. This connection between type I IFN, trained immunity and cholesterol metabolism may have important implications for pSS and the pathogenesis of (subclinical) atherosclerosis in these patients. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289449/ /pubmed/35860283 http://dx.doi.org/10.3389/fimmu.2022.840751 Text en Copyright © 2022 Huijser, van Helden-Meeuwsen, Grashof, Tarn, Brkic, Huisman, Wahadat, van de Werken, Lopes, van Roon, van Daele, Kamphuis, Ng, Bekkering, Joosten, Dik and Versnel https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Huijser, Erika
van Helden-Meeuwsen, Cornelia G.
Grashof, Dwin G. B.
Tarn, Jessica R.
Brkic, Zana
Huisman, Josje M. A.
Wahadat, M. Javad
van de Werken, Harmen J. G.
Lopes, Ana P.
van Roon, Joel A. G.
van Daele, Paul L. A.
Kamphuis, Sylvia
Ng, Wan-Fai
Bekkering, Siroon
Joosten, Leo A. B.
Dik, Willem A.
Versnel, Marjan A.
Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
title Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
title_full Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
title_fullStr Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
title_full_unstemmed Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
title_short Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
title_sort trained immunity in primary sjögren’s syndrome: linking type i interferons to a pro-atherogenic phenotype
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289449/
https://www.ncbi.nlm.nih.gov/pubmed/35860283
http://dx.doi.org/10.3389/fimmu.2022.840751
work_keys_str_mv AT huijsererika trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT vanheldenmeeuwsencorneliag trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT grashofdwingb trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT tarnjessicar trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT brkiczana trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT huismanjosjema trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT wahadatmjavad trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT vandewerkenharmenjg trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT lopesanap trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT vanroonjoelag trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT vandaelepaulla trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT kamphuissylvia trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT ngwanfai trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT bekkeringsiroon trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT joostenleoab trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT dikwillema trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype
AT versnelmarjana trainedimmunityinprimarysjogrenssyndromelinkingtypeiinterferonstoaproatherogenicphenotype